The Impact of New, Nonproprietary Naming Convention for Biologics and Biosimilars: 7 Key Findings
Tony Schueth, HealthTech Zone, November 30, 2017
Link
FDA Issues Guidance on Naming Conventions and Interchangability for Biologics and Biosimilars – Link
By Pooja Babbrah, POCP Blog, February 16, 2017
NCPDP Action Group Focused on Biologics and Biosimilars – Link
By Brian Bamberger, POCP Blog, September 2016
Why EHRs Will Have Different Documentation Requirements for Biosimilar Dispensing, Administration, and Outcomes – Link
Tony Schueth, HISTalk, July 11, 2016
Biosimilar Legislative Trend Means Big Changes for EHRs – Link
by Connie Sinclair, POCP Blog, April 2016
Biosimilars 101: Considerations for Health IT and Other Stakeholders – Link
by Tony Schueth, POCP Blog, April 2016
Alerting Prescribers for Biosimilar Substation to Protect Patient Safety – Link
by Pooja Babbrah, HIT Perspectives, April 2016
Readers Write: Three Reasons EHRs Need to Treat Biosimilars Differently Than Generics – Link
by Tony Schueth, HISTalk, April 13, 2016
Top Ten Health IT Trends for 2016 – Link
by Tony Schueth, POCP Blog, February 2016
Paving the Way for Specialty ePrescribing – Link
by Tony Schueth, HIT Perspectives, September 2015
DERF-a-Palooza at May NCPDP Meeting Yields Results – Link
by Michael Burger, HIT Perspectives, June 2016
Exciting Changes Ahead in 2015 for HealthIT – Link
by Tony Schueth, HIT Perspectives, February 2015
Biosimilar Recommendation Means Challenges and Opportunities Ahead for HealthIT – Link
by Tony Schueth, POCP Blog, January 2015
